Please assess the completion status of the following clinical trial:

Trial Title: Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Patients eligible for inclusion in this study had to fulfill all of the following criteria:~* Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)~* Rheumatoid factor and anti-CCP antibodies negative at screening~* Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or documented history of plaque psoriasis~* Subjects with PsA should have taken NSAIDs for at least 4 weeks prior to randomization with inadequate control of symptoms or at least one dose if stopped due to intolerance to NSAIDs~* Subjects taking corticosteroids must be on a stable dose of ≤10 mg/day prednisone or equivalent for at least 2 weeks before randomization and should remain on a stable dose up to Week 16~* Subjects taking MTX (≤ 25 mg/week) are allowed to continue their medication if the dose is stable for at least 4 weeks before randomization and should remain on a stable dose up to Week 52.~Patients fulfilling any of the following criteria are not eligible for inclusion in this study:~* Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician~* Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine)~* Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor~* Ongoing use of prohibited psoriasis treatments / medications (e.g., topical corticosteroids, UV therapy) at randomization. The following wash-out periods need to be observed:~* Oral or topical retinoids- 4 weeks~* Photochemotherapy (e.g. PUVA)- 4 weeks~* Phototherapy (UVA or UVB)- 2 weeks~* Topical skin treatments (except in face, eyes, scalp and genital area during screening, only corticosteroids with mild to moderate potency)- 2 weeks~* Any intramuscular or intravenous corticosteroid treatment within 4 weeks before randomization.~* Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before randomization.~* Subjects who have previously been treated with more than 3 different TNF inhibitors (investigational or approved).~* Subjects who have ever received biologic immunomodulating agents, investigational or approved except for those targeting TNFα.~* Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- AIN457 6 mg/kg - 3 mg/kg i.v. (Type: EXPERIMENTAL): AIN457 6 mg/kg i.v. infusion at baseline, followed by AIN457 3 mg/kg i.v. infusion every 4 weeks starting at Week 4 through Week 48 (exposure through Week 52).
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo from baseline to Week 16 and switch to AIN457 3mg/kg i.v. infusion every 4 weeks through Week 48 (exposure through Week 52).

Based on this trial design, predict the completion outcome and termination type (if applicable).